查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403438

到 2030 年的製药建模软体市场预测：按组件、部署、作业系统、公司规模、采购模式、应用程式、最终用户和地区进行的全球分析

Drug Modeling Software Market Forecasts to 2030 - Global Analysis By Component, By Deployment, Operating System, Enterprise Size, Purchasing Model, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球製药建模软体市场规模将达到 77 亿美元，预计到 2030 年将达到 155 亿美元，预测期内复合年增长率为 10.5%。

药物建模软体是指采用演算法和模拟来预测、分析和优化药物发现和药物研发方面的计算工具。这些程序有助于理解分子交互作用、药物动力学和药物-标靶相互作用。对生物系统、化学结构和药物行为进行模拟和建模有助于设计、筛检和优化潜在的候选药物，并提高药物研发过程的效率和成功率。

据美国研究和製药工业协会称，成功的药物研发平均花费 26 亿美元。

新疗法的需求不断增长

随着复杂疾病的流行和治疗要求的不断变化，对创新和有效治疗方法的需求日益增长。药物建模软体可以探索和预测模拟不同的分子结构，从而促进潜在候选药物的识别和优化。这种技术主导的方法不仅加速了药物研发过程，而且还支持定制治疗方法的设计，满足更精确、更有针对性和更有效的治疗方法的需求，从而促进医疗保健我们支持软体的重要性和普及在促进创新方面。

检验和准确性挑战

确保预测模型的准确性和可靠性需要对实验资料进行广泛的验证，这通常需要大量的时间和资源。此外，复杂的生物系统以及药物和标靶之间的多样化交互作用会影响软体的预测能力，并导致准确性挑战。准确再现现实世界复杂性的限制阻碍了软体的有效性，需要不断的改进和检验工作。

人们对云端基础的分析和资料处理越来越感兴趣

云端平台提供了可扩展、经济高效的基础设施，可以处理庞大的资料集和复杂的运算。这种转变可以实现更好的协作、更快的处理速度以及更好地存取高阶建模工具。此外，云端基础的解决方案有助于与其他应用程式无缝集成，并实现全球研究人员之间的即时资料共用。拥抱这一趋势不仅可以简化工作流程，还可以促进创新，使组织能够利用最尖端科技并优化成本和资源利用率，同时推动药物研发发现和开发的进步。一定会的。

资料隐私和安全问题

对资料隐私和安全的担忧对药物建模软体市场构成了重大威胁。药物开发中患者资料和专有资讯的敏感性引起了人们对潜在违规、未授权存取和资料滥用的担忧。安全缺陷可能会削弱信任，影响采用率，并破坏製药公司和软体供应商之间的合作。此外，GDPR 和 HIPAA 等严格法规对医疗保健资料的处理施加了严格的标准，这加大了软体开发人员确保合规性的压力。

COVID-19 的影响：

COVID-19 大流行加速了药物建模软体的采用，并加强了其在远端药物开发和虚拟临床试验中的作用。这增加了对快速药物设计和重新利用的预测分析和计算方法的依赖，促进对新出现的健康危机的快速反应。然而，研究和临床活动的中断暂时影响了市场成长。然而，这场大流行凸显了软体的重要性，刺激了创新并加强了其在敏捷和远端药物开发过程中的关键作用。

在预测期内，医院和医疗保健提供者行业预计将是最大的。

由于利用先进软体进行个体化治疗策略、药物疗效预测和治疗优化的趋势不断增强，医院和医疗保健提供者领域预计将引领药物建模软体市场。专注于精准医疗的医院和医疗保健提供者依靠药物建模软体来提供临床决策支持，以改善患者的治疗效果。此外，将这些工具整合到电子健康记录中有助于无缝实施，有助于在该领域占据主导地位。

预测期内，药物研发和开发领域预计复合年增长率最高

由于对新治疗药物的需求持续激增，药物研发发现和开发领域预计将显着增长。药物开发商越来越依赖先进的建模软体来快速识别、设计和优化潜在的候选药物。此外，人工智慧和机器学习的整合进一步提高了效率，推动了製药建模软体市场这一细分市场的显着成长预测。

比最大的地区

由于强大的製药和生物技术领域，北美预计将引领製药建模软体市场。该地区拥有大量研发投资、先进的医疗基础设施以及主要行业参与者。此外，该地区对创新和技术采用的重视，以及对个人化医疗和精准药物开发的高需求，也推动了先进建模软体的使用。这些因素，加上支持性的法律规范和早期采用新技术的文化，使北美在药物建模软体市场中处于主导地位。

复合年增长率最高的地区：

由于製药和生物技术行业的快速成长以及研发投资的增加，预计亚太地区的製药建模软体市场将显着成长。此外，大量临床试验患者群的存在以及对精准医疗的日益关注也推动了药物建模软体的采用。此外，扩大医疗基础设施、技术进步和政府支援措施正在推动该地区的成长。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球製药建模软体市场：按组成部分

  • 软体
  • 资料库

第六章全球製药建模软体市场：依部署分类

  • 云端基础
  • 混合基地
  • 本地

第七章全球製药建模软体市场：按作业系统

  • Windows
  • Linux
  • Mac Os
  • 其他作业系统

第八章全球製药建模软体市场：依公司规模

  • 大公司
  • 中小企业

第九章全球製药建模软体市场：依购买模式分类

  • 基于订阅
  • 一次许可证

第 10 章全球製药建模软体市场：按应用分类

  • 细胞模拟
  • 化学资讯学
  • 疾病建模
  • 药物研发发现与开发
  • 基因序列分析
  • 图形分子建模
  • 医疗图像
  • 蛋白质建模
  • 其他用途

第十一章全球製药建模软体市场：依最终用户分类

  • 合约研究组织（CRO）
  • 製药和生物技术公司
  • 医院和医疗保健提供者
  • 其他最终用户

第10章全球製药建模软体市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Acellera
  • Biovia
  • Certara
  • Chemical Computing Group
  • Collaborative Drug Discovery, Inc.
  • Cresset
  • Genedata AG
  • Insilico Medicine
  • Instinctools GmbH
  • Leadscope, Inc.
  • Molecular Networks GmbH
  • Nimbus Therapeutics
  • Numerate, Inc.
  • OpenEye Scientific Software
  • Optibrium Ltd.
  • Pharmacelera
  • Physiomics plc
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
Product Code: SMRC24663

According to Stratistics MRC, the Global Drug Modeling Software Market is accounted for $7.7 billion in 2023 and is expected to reach $15.5 billion by 2030 growing at a CAGR of 10.5% during the forecast period Drug Modeling Software refers to computational tools employing algorithms and simulations to predict, analyze and optimize aspects of drug discovery and development. These programs facilitate the understanding of molecular interactions, pharmacokinetics and drug-target interactions. By simulating and modeling biological systems, chemical structures and drug behavior, they aid in designing, screening and optimizing potential drug candidates, enhancing the efficiency and success rates of pharmaceutical research and development processes.

According to the Pharmaceutical Research and Manufacturers of America, a successful drug's research and development cost an average of US$2.6 BN.

Market Dynamics:

Driver:

Growing need for novel treatments

With an increasing prevalence of complex diseases and evolving therapeutic requirements, there's a pressing need for innovative and effective treatments. Drug modeling software enables the exploration of diverse molecular structures and predictive simulations, expediting the identification and optimization of potential drug candidates. This technology-driven approach not only accelerates the discovery process but also aids in designing tailored therapies, meeting the demand for more precise, targeted and efficacious treatments, consequently propelling the software's significance and adoption in advancing healthcare innovation.

Restraint:

Validation and precision challenges

Ensuring the accuracy and reliability of predictive models requires extensive validation against experimental data, often demanding substantial time and resources. Additionally, complex biological systems and the diverse interactions between drugs and targets contribute to precision challenges, impacting the software's predictive capabilities. The limitations of accurately replicating real-world complexities hinder the software's effectiveness, necessitating continuous refinement and validation efforts.

Opportunity:

Rising interest in cloud-based analytics and data processing

Cloud platforms offer scalable, cost-effective infrastructure capable of handling vast datasets and complex computations. This shift allows for enhanced collaboration, faster processing speeds and greater accessibility to sophisticated modeling tools. Moreover, cloud-based solutions facilitate seamless integration with other applications and enable real-time data sharing among researchers globally. Embracing this trend not only streamlines workflows but also fosters innovation, empowering organizations to leverage cutting-edge technologies and drive advancements in drug discovery and development while optimizing costs and resource utilization.

Threat:

Data privacy and security concerns  

Data privacy and security concerns pose a significant threat to the drug modeling software market. The sensitive nature of patient data and proprietary information in drug development raises apprehensions about potential breaches, unauthorized access or data misuse. Instances of security lapses could erode trust, impact adoption rates, and hinder collaboration between pharmaceutical entities and software providers. Moreover, stringent regulations like GDPR and HIPAA impose rigorous standards for handling healthcare data, augmenting the pressure on software developers to ensure compliance.

COVID-19 Impact:

The COVID-19 pandemic accelerated the adoption of drug modeling software, intensifying its role in remote drug development and virtual clinical trials. It prompted a heightened reliance on predictive analytics and computational methods for rapid drug design and repurposing, facilitating faster responses to emerging health crises. However, disruptions in research and clinical activities temporarily affected market growth. Yet, the pandemic underscored the software's criticality, spurring innovation and reinforcing its pivotal role in agile and remote drug development processes.

The hospitals & healthcare providers segment is expected to be the largest during the forecast period

The hospitals and healthcare providers segment is anticipated to lead the drug modeling software market due to its increasing leverage of advanced software for personalized treatment strategies, drug efficacy predictions and treatment optimization. With a focus on precision medicine, hospitals and healthcare providers utilize drug modeling software for clinical decision support, enhancing patient care outcomes. Additionally, the integration of these tools into electronic health records facilitates seamless implementation, contributing to the segment's dominance.

The drug discovery and development segment is expected to have the highest CAGR during the forecast period

The drug discovery and development segment is poised for significant growth owing to the continuous surge in demand for novel therapeutics. Drug developers increasingly rely on advanced modeling software to expedite the identification, design and optimization of potential drug candidates. Additionally, the integration of artificial intelligence and machine learning further enhances efficiency, driving the substantial anticipated growth of this segment within the drug modeling software market.

Region with largest share:

North America is anticipated to lead the drug modeling software market due to its robust pharmaceutical and biotech sectors. The region boasts significant R&D investments, advanced healthcare infrastructure and a strong presence of major industry players. Moreover, the region's emphasis on innovation and technology adoption, coupled with a high demand for personalized medicine and precision drug development, drives the use of sophisticated modeling software. These factors, combined with supportive regulatory frameworks and a culture of early adoption of novel technologies, position North America to dominate the drug modeling software market.

Region with highest CAGR:

Asia Pacific is poised for substantial growth in the drug modeling software market due to the region's burgeoning pharmaceutical and biotech industries, coupled with increasing R&D investments. Additionally, the presence of a vast patient pool for clinical trials and a growing emphasis on precision medicine foster the adoption of drug modeling software. Moreover, expanding healthcare infrastructure, technological advancements and supportive government initiatives propel growth in this region.

Key players in the market:

Some of the key players in drug modeling software market include Acellera, Biovia, Certara, Chemical Computing Group, Collaborative Drug Discovery, Inc., Cresset, Genedata AG, Insilico Medicine, Instinctools GmbH, Leadscope, Inc., Molecular Networks GmbH, Nimbus Therapeutics, Numerate, Inc., OpenEye Scientific Software, Optibrium Ltd., Pharmacelera, Physiomics plc, Schrodinger, Inc. and Simulations Plus, Inc.

Key Developments:

In May 2023, Cresset announced the latest release of molecular modeling platform that delivers improved efficiencies for small molecule discovery therefore Flare V7. This helps the organisation developing more revenue.

In May 2023, Fujitsu launched the Biodrug Design Accelerator platform to increase peptide drug discovery research. This platform helps peptide drug discovery scientists in pharmaceutical industries to speed up and increases the efficiency of peptide drug development, especially through the cycles "design, make, test, analyze" (DMTA), ultimately allowing faster and informed design of peptide drug candidates and effective communication among scientists about synthesis and testing.

In February 2023, Accenture has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company that has developed advanced computational platforms to assist biopharma companies to discover and develop more effective diagnostics and therapeutics.

Components Covered:

  • Software
  • Database

Deployments Covered:

  • Cloud Based
  • Hybrid-Based
  • On-Premises

Operating Systems Covered:

  • Windows
  • Linux
  • Mac Os
  • Other Operating Systems

Enterprise Sizes Covered:

  • Large Enterprise Size
  • Small & Medium Enterprise Size

Purchasing Models Covered:

  • Subscription Based
  • One-Time License

Applications Covered:

  • Cellular Simulation
  • Cheminformatics
  • Disease Modeling
  • Drug Discovery and Development
  • Gene Sequence Analysis
  • Graphical Molecular Modeling
  • Medical Imaging
  • Protein Modeling
  • Other Applications

End Users Covered:

  • Contract Research Organizations (CROs)
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Healthcare Providers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Modeling Software Market, By Component

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Database

6 Global Drug Modeling Software Market, By Deployment

  • 6.1 Introduction
  • 6.2 Cloud Based
  • 6.3 Hybrid-Based
  • 6.4 On-Premises

7 Global Drug Modeling Software Market, By Operating System

  • 7.1 Introduction
  • 7.2 Windows
  • 7.3 Linux
  • 7.4 Mac Os
  • 7.5 Other Operating Systems

8 Global Drug Modeling Software Market, By Enterprise Size

  • 8.1 Introduction
  • 8.2 Large Enterprise Size
  • 8.3 Small & Medium Enterprise Size

9 Global Drug Modeling Software Market, By Purchasing Model

  • 9.1 Introduction
  • 9.2 Subscription Based
  • 9.3 One-Time License

10 Global Drug Modeling Software Market, By Application

  • 10.1 Introduction
  • 10.2 Cellular Simulation
  • 10.3 Cheminformatics
  • 10.4 Disease Modeling
  • 10.5 Drug Discovery and Development
  • 10.6 Gene Sequence Analysis
  • 10.7 Graphical Molecular Modeling
  • 10.8 Medical Imaging
  • 10.9 Protein Modeling
  • 10.10 Other Applications

11 Global Drug Modeling Software Market, By End User

  • 11.1 Introduction
  • 11.2 Contract Research Organizations (CROs)
  • 11.3 Pharmaceutical & Biotechnology Companies
  • 11.4 Hospitals & Healthcare Providers
  • 11.5 Other End Users

10 Global Drug Modeling Software Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Acellera
  • 12.2 Biovia
  • 12.3 Certara
  • 12.4 Chemical Computing Group
  • 12.5 Collaborative Drug Discovery, Inc.
  • 12.6 Cresset
  • 12.7 Genedata AG
  • 12.8 Insilico Medicine
  • 12.9 Instinctools GmbH
  • 12.10 Leadscope, Inc.
  • 12.11 Molecular Networks GmbH
  • 12.12 Nimbus Therapeutics
  • 12.13 Numerate, Inc.
  • 12.14 OpenEye Scientific Software
  • 12.15 Optibrium Ltd.
  • 12.16 Pharmacelera
  • 12.17 Physiomics plc
  • 12.18 Schrodinger, Inc.
  • 12.19 Simulations Plus, Inc.

List of Tables

  • Table 1 Global Drug Modeling Software Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Modeling Software Market Outlook, By Component (2021-2030) ($MN)
  • Table 3 Global Drug Modeling Software Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Drug Modeling Software Market Outlook, By Database (2021-2030) ($MN)
  • Table 5 Global Drug Modeling Software Market Outlook, By Deployment (2021-2030) ($MN)
  • Table 6 Global Drug Modeling Software Market Outlook, By Cloud Based (2021-2030) ($MN)
  • Table 7 Global Drug Modeling Software Market Outlook, By Hybrid-Based (2021-2030) ($MN)
  • Table 8 Global Drug Modeling Software Market Outlook, By On-Premises (2021-2030) ($MN)
  • Table 9 Global Drug Modeling Software Market Outlook, By Operating System (2021-2030) ($MN)
  • Table 10 Global Drug Modeling Software Market Outlook, By Windows (2021-2030) ($MN)
  • Table 11 Global Drug Modeling Software Market Outlook, By Linux (2021-2030) ($MN)
  • Table 12 Global Drug Modeling Software Market Outlook, By Mac Os (2021-2030) ($MN)
  • Table 13 Global Drug Modeling Software Market Outlook, By Other Operating Systems (2021-2030) ($MN)
  • Table 14 Global Drug Modeling Software Market Outlook, By Enterprise Size (2021-2030) ($MN)
  • Table 15 Global Drug Modeling Software Market Outlook, By Large Enterprise Size (2021-2030) ($MN)
  • Table 16 Global Drug Modeling Software Market Outlook, By Small & Medium Enterprise Size (2021-2030) ($MN)
  • Table 17 Global Drug Modeling Software Market Outlook, By Purchasing Model (2021-2030) ($MN)
  • Table 18 Global Drug Modeling Software Market Outlook, By Subscription Based (2021-2030) ($MN)
  • Table 19 Global Drug Modeling Software Market Outlook, By One-Time License (2021-2030) ($MN)
  • Table 20 Global Drug Modeling Software Market Outlook, By Application (2021-2030) ($MN)
  • Table 21 Global Drug Modeling Software Market Outlook, By Cellular Simulation (2021-2030) ($MN)
  • Table 22 Global Drug Modeling Software Market Outlook, By Cheminformatics (2021-2030) ($MN)
  • Table 23 Global Drug Modeling Software Market Outlook, By Disease Modeling (2021-2030) ($MN)
  • Table 24 Global Drug Modeling Software Market Outlook, By Drug Discovery and Development (2021-2030) ($MN)
  • Table 25 Global Drug Modeling Software Market Outlook, By Gene Sequence Analysis (2021-2030) ($MN)
  • Table 26 Global Drug Modeling Software Market Outlook, By Graphical Molecular Modeling (2021-2030) ($MN)
  • Table 27 Global Drug Modeling Software Market Outlook, By Medical Imaging (2021-2030) ($MN)
  • Table 28 Global Drug Modeling Software Market Outlook, By Protein Modeling (2021-2030) ($MN)
  • Table 29 Global Drug Modeling Software Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 30 Global Drug Modeling Software Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Drug Modeling Software Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
  • Table 32 Global Drug Modeling Software Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 33 Global Drug Modeling Software Market Outlook, By Hospitals & Healthcare Providers (2021-2030) ($MN)
  • Table 34 Global Drug Modeling Software Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.